The web site you wish to link to is owned or operated by an entity other than ASLAN Pharmaceuticals. We do not control this third party web site. We are providing this link for your convenience only and we are not responsible for the availability of or the content located on or through this third party web site, the accuracy, completeness, timeliness, or legality of any information contained in this third party web site, and any opinions expressed therein, nor for any link contained in this third party web site. This third party web site is not investigated, monitored, or checked for accuracy, completeness, timeliness, or legality, by ASLAN Pharmaceuticals Limited. The link from our web site to this third party web site does not imply that we approve of, endorse, or recommend this third party web site. We expressly disclaim all warranties, express or implied, as to the accuracy, legality, reliability, timeliness, quality, or validity of any content on this third party web site.
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
Led by a management team with extensive global pharma and biotech experience, ASLAN collaborates with internationally renowned experts and institutions to develop drugs – turning ground breaking research into effective therapies for those in need.
We focus on Asia prevalent tumour types, including gastric cancer, biliary tract cancer and breast cancer. As few effective therapies exist to treat these diseases, there is a significant unmet need globally.
Our Therapeutic Areas include: Cholangiocarcinoma Gastric cancer Breast cancer
Through our presence in Singapore, Taiwan, China and Australia, we develop drugs across the Asia Pacific region, then leverage the data for global registration, with the potential for accelerated approvals in countries where these indications are considered orphan diseases.
We have offices in Singapore, Taipei, Shanghai and Australia, and conduct regional clinical development programmes across Asia.
Founded in 2010, ASLAN has rapidly established a strong track record in oncology-focused product development. Since its founding, ASLAN has raised over US$100 million in financing, formed innovative partnerships with pharmaceutical industry leaders and developed four therapeutic medicines that target cancers for which there are few effective treatments.